Bhavana Konda

Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (19)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Background Lutetium-177 ( 177 Lu)-DOTATATE is an effective treatment for metastatic gastroenteropancreatic (GEP) NETs. However, radiation can cause transient inflammation/swelling of tumors, which can result in toxicity. Treatment-related small bowel obstruction associated with mesenteric or peritoneal disease has been described. We investigated the potential for intestinal ischemia in 177 Lu-DOTATATE-treated patients. Methods Clinical records were reviewed of patients with midgut NETs treated with 177 Lu-DOTATATE at the Moffitt Cancer Center between April 2018 and December 2022 and at The Ohio State University between December 2017 and October 2020. Results Among the cases reviewed, we identified three patients who developed bowel ischemia/perforation shortly after their initial treatment with 177 Lu-DOTATATE. All patients had metastatic small bowel NET with prominent mesenteric mass encasing/obstructing the mesenteric vessels and preexisting symptoms of postprandial abdominal pain. Conclusion Acute bowel ischemia may be a rare complication of PRRT in patients with mesenteric arterial or venous obstruction from mesenteric metastasis.

Year:

2025

Year:

2025

Background This investigator-initiated phase II trial aimed to evaluate the efficacy of cabozantinib in combination with nivolumab and ipilimumab (CaboNivoIpi) in previously treated patients with radioactive iodine-refractory differentiated thyroid cancer. Methods Eligible patients with radioactive iodine-refractory differentiated thyroid cancer who progressed on 1 prior line of vascular endothelial growth factor receptor-targeted therapy received a 2-week run-in of cabozantinib monotherapy followed by CaboNivoIpi for 4 cycles (cycle length = 6 weeks), followed by cabozantinib plus nivolumab (cycle length = 4 weeks) until disease progression. The primary endpoint was objective response rate (ORR) within the first 6 months of treatment. A Simon optimal 2-stage design allowed for an interim analysis after accrual of 10 evaluable patients. At least 5 responses were needed to proceed to stage 2. Results Among 11 patients enrolled, the median age was 69 years. Prior vascular endothelial growth factor receptor-targeted therapies included lenvatinib, pazopanib, and sorafenib plus everolimus. Median follow-up was 13.4 months. Among 10 evaluable patients, ORR within the first 6 months of treatment was 10% (1 partial response). Median progression-free survival was 9 months (95% CI, 3.0–not reached) and median overall survival was 19.2 months (95% CI, 4.6–not reached). Grade 3/4 treatment-related adverse events (AEs) were noted in 55% (6/11) and grade 5 AEs in 18% (2/11) of patients. The most common treatment-related AE was hypertension. The study did not reach its prespecified efficacy threshold. Conclusion CaboNivoIpi had low ORRs and a high rate of grade ≥3 treatment-related AEs. Clinical Trial Registration NCT03914300

Year:

2025

Evaluation of circulating CD4+ T cell subsets. (A) Changes in regulatory T cells (Tregs) during treatment compared to screening in the entire patient cohort. (B) Changes in levels of circulating CD4+ naïve (CD45RA+ CCR7+), central memory (CM; CD45RA- CCR7+), effector memory (EM; CD45RA- CCR7-), and terminal effector memory (TE; CD45RA+ CCR7-) subsets at screening and cycle 1, day 15 (C1D15) of nivolumab and temozolomide treatment in the entire study cohort. (C) Levels of co-inhibitory molecules PD-1, LAG3, TIM3, and KLRG1 on circulating CD4+ T cells on study treatment compared to screening. Each symbol represents one patient (n = 9). Line indicates mean, *p

Year:

2025

Evaluation of circulating CD8+ cell subsets. (A) Changes in levels of circulating CD8+ naïve (CD45RA+ CCR7+), central memory (CM; CD45RA- CCR7+), effector memory (EM; CD45RA- CCR7-), and terminal effector memory (TE; CD45RA+ CCR7-) subsets at screening and cycle 1, day 15 (C1D15) of nivolumab and temozolomide treatment in the entire study cohort. (B) Levels of co-inhibitory molecules PD-1, LAG3, TIM3, and KLRG1 on circulating CD8+ T cells on study treatment compared to screening. Each symbol represents one patient (n = 9). Line indicates mean, *p

Year:

2025

Evaluation of circulating MDSC. (A) Changes in total MDSC and (B) monocytic (M-MDSC) and granulocytic (G-MDSC) subsets at cycle 1, day 15 (C1D15) compared to screening in the entire patient cohort. (C) Levels of circulating MDSC at screening by clinical response and changes during study treatment compared to screening in partial response (PR, orange) and stable disease (SD, green) patients. Each symbol represents one patient (n = 9). Line indicates mean.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (14)

Paul J. Norman

-

UNITED STATES
View details

Vineeth Sukrithan

Assistant Professor of Medicine

The Ohio State University Wexner Medical Center

UNITED STATES
View details

Lai Wei

Research Assistant Professor

Ohio State University

UNITED STATES
View details

Ticiana Della Justina Farias

Research Assistant Professor

University of North Carolina at Charlotte

UNITED STATES
View details

Timothy Burns

Professor

University of Pittsburgh

UNITED STATES
View details

Thorvardur Halfdanarson

Professor of Oncology

Mayo Clinic

UNITED STATES
View details

Heloisa Soares

Associate Professor

Huntsman Cancer Institute

UNITED STATES
View details

Daniel W. Bowles

Associate Professor

-

UNITED STATES
View details

Robert Wesolowski

Assistant Professor

Ohio State University

UNITED STATES
View details

Nancy A Curtis

Ohio State University

UNITED STATES
View details

Dwight H. Owen

Ohio State University

UNITED STATES
View details

Yuri E. Nikiforov

Vice Chair

UPMC Presbyterian

UNITED STATES
View details

William E. Carson, III

Professor

Ohio State University

UNITED STATES
View details

Alex Blair

Assistant Professor of Surgery

The Ohio State University Comprehensive Cancer Center

UNITED STATES
View details